eligibility_summary
Met/unresectable tumors, no SOC options. A/B: CRC, GC/GEJ, NSCLC, PDAC. C: CRC (prior FP+OXA+IRI), PDAC (1–3 lines), GC/GEJ (prior platinum/FP), NSCLC (prior platinum, PD-1/PD-L1/targeted if eligible), SCLC (platinum, ≤3 lines). D/E: metastatic CRC + bevacizumab, E ≤2 prior lines, prior FP/IRI/OXAL ± anti-VEGF/anti-EGFR (RAS WT). ECOG 0–1, measurable disease, biopsy B/C/E. Exclude prior CEACAM5/camptothecin-ADC, recent malignancy, active CNS, bevacizumab hypersensitivity/bleeding risks.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial: NCT06131840 (Phase 1). Interventions: PF-08046050 (SGN-CEACAM5C, SAR445953), an antibody-drug conjugate (ADC) targeting CEACAM5 (CEA), and PF-08046050 combined with bevacizumab. Mechanisms: SGN-CEACAM5C is a CEACAM5-directed monoclonal antibody linked to a camptothecin-class topoisomerase I inhibitor, it binds CEACAM5 on tumor cells, is internalized, and releases payload to cause DNA damage and cell death. Bevacizumab is an anti-VEGF-A monoclonal antibody that inhibits angiogenesis by blocking VEGF/VEGFR signaling. Targets: CEACAM5-expressing epithelial tumor cells (notably CRC, GC/GEJ, PDAC, NSCLC, SCLC), pathways affected include tumor cell TOP1-mediated DNA replication and tumor vasculature/angiogenesis via VEGF. Aim: establish dose, safety, and preliminary activity of SGN-CEACAM5C alone and with bevacizumab in advanced/metastatic solid tumors.